<DOC>
	<DOCNO>NCT01464788</DOCNO>
	<brief_summary>Randomized control clinical trial estimate overall treatment benefit ( improvement disability ) among stroke patient treat rt-PA randomized also receive either low-dose Argatroban , high-dose Argatroban neither .</brief_summary>
	<brief_title>Randomized Controlled Trial Argatroban With Tissue Plasminogen Activator ( tPA ) Acute Stroke</brief_title>
	<detailed_description>Recombinant tissue plasminogen activator ( rt-PA ) , proven treatment acute ischemic stroke , fail reperfuse brain patient large thrombus . In Phase 2a low-dose safety study ( n=65 ) , two drug appear safe deliver concomitantly recanalization rate great historical control . This study provide evidence-based hypothesis data need design large definitive trial . The purpose trial estimate overall treatment benefit ( improvement disability ) among stroke patient treat rt-PA randomized also receive either low-dose Argatroban , high-dose Argatroban neither .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<mesh_term>Argatroban</mesh_term>
	<criteria>1 . Disabling Ischemic stroke symptom onset &lt; 3 hour treat IV rtPA local standards* . * ≤ 4.5 hour accord local standard care . 2 . Age ≥18 . 3 . NIHSS ≥ 10* NIHSS intracranial clot demonstrate neurovascular imaging ( TCD CTA ) one follow area : distal internal carotid artery ( ICA ) carotid artery ( CA ) , middle cerebral artery ( MCA M1 M2 ) , posterior cerebral artery ( PCA P1 P2 ) , distal vertebral basilar artery . TCD criterion : Thrombolysis brain ischemia ( TIBI ) 0 , 1 , 2 3 CTAngiogram : thrombolysis myocardial ischemia ( TIMI ) 0 1 * NIHSS ≥ 10 , demonstration clot neuroimaging necessary ( i.e. , enrollment proceed noncontrast head CT alone ) , perform , clot must demonstrate . 4 . For patient undergo repeat CTAngiogram 23 hour , estimate glomerular filtration rate ( eGFR ) must ≥ 60 mL/min/1.73m2 . 5 . Females childbearing potential must negative serum pregnancy test ( HCG ) prior administration trial medication . 6 . Signed ( write ) inform consent patient patient 's legal representative and/or guardian . 1 . Patients treat physician planning ( could plan ) treat intraarterial thrombolysis endovascular procedure ( i.e. , mechanical clot retrieval ) aim recanalization . 2 . Evidence intracranial hemorrhage ( ICH ) baseline CT scan diagnosis nonvascular cause neurologic deficit . 3 . National institute health stroke scale ( NIHSS ) Level Consciousness score ( 1a ) ≥ 2 . 4 . Preexisting disability mRS ≥ 2 . 5 . CT scan finding hypoattenuation xray signal ( hypodensity ) involve ≥ 1/3 MCA territory . 6 . Any evidence clinically significant bleeding , know coagulopathy . 7 . INR &gt; 1.5 . 8 . Patients elevate activated partial thromboplastin time ( aPTT ) great upper limit normal 9 . Patients currently , within previous 24 hour , oral direct thrombin inhibitor ( i.e. , dabigatran ) . 10 . Heparin flush require IV line . Line flush saline . 11 . Any history intracranial hemorrhage , know arteriovenous malformation unsecured cerebral aneurysm . 12 . Significant bleed episode [ e.g . gastrointestinal ( GI ) urinary tract ] within 3 week study enrollment . 13 . Major surgery serious trauma last 2 week . 14 . Patients arterial puncture noncompressible site , biopsy parenchymal organ , lumbar puncture within last 2 week . 15 . Previous stroke , myocardial infarction ( MI ) , post myocardial infarction pericarditis , intracranial surgery , significant head trauma within 3 month . 16 . Uncontrolled hypertension [ Systolic blood pressure ( SBP ) &gt; 185 mmHg diastolic blood pressure ( DBP ) &gt; 110 mmHg ] respond intravenous antihypertensive agent . 17 . Surgical intervention ( reason ) anticipate within next 48 hour . 18 . Known history clinically significant hepatic dysfunction liver disease include current history alcohol abuse . 19 . Abnormal blood glucose &lt; 50 mg/dL ( 2.7 mmol/L ) . 20 . History primary metastatic brain tumor . 21 . Current platelet count &lt; 100,000/mm3 . 22 . Life expectancy &lt; 3 month . 23 . Patient , judgment investigator , need concomitant ( i.e. , Argatroban infusion ) anticoagulants Argatroban , include form heparin , unfractionated heparin ( UFH ) , low molecular weight heparin ( LMWH ) , defibrinogenating agent , dextran , direct thrombin inhibitor thrombolytic agent , glycoprotein llb/llla ( GPIIb/IIIa ) inhibitor warfarin . 24 . Participated investigational study within 30 day first dose study medication . 25 . Known hypersensitivity Argatroban agent . 26 . Additional exclusion criterion patient present 34.5 hour : 1 . Age &gt; 80 2 . Currently take oral anticoagulant ( regardless INR ) 3 . A history stroke diabetes . 4 . NIHSS &gt; 25 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>stroke</keyword>
	<keyword>Argatroban</keyword>
	<keyword>thrombin-inhibition</keyword>
	<keyword>thrombolysis</keyword>
	<keyword>anticoagulation</keyword>
</DOC>